Total Payments
$132.70
2022 Payments
$25.97
Companies
5
Transactions
7
Medicare Patients
7,913
Medicare Billing
$635,437
Payment Breakdown by Category
Food & Beverage$132.70 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $132.70 | 7 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $46.85 | 3 | $0 (2020) |
| Boston Scientific Corporation | $25.97 | 1 | $0 (2022) |
| Amgen Inc. | $23.01 | 1 | $0 (2018) |
| Neos Therapeutics, LP | $19.80 | 1 | $0 (2017) |
| Genentech USA, Inc. | $17.07 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $25.97 | 1 | Boston Scientific Corporation ($25.97) |
| 2020 | $16.15 | 1 | Merck Sharp & Dohme Corporation ($16.15) |
| 2018 | $70.78 | 4 | Merck Sharp & Dohme Corporation ($30.70) |
| 2017 | $19.80 | 1 | Neos Therapeutics, LP ($19.80) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/10/2022 | Boston Scientific Corporation | General - Pain Management (Device) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: General - Pain Management_NMD | ||||||
| 01/23/2020 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), STEGLATRO, STEGLUJAN | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/21/2018 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Virology & Specialty Care | ||||||
| 07/31/2018 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), STEGLATRO, DULERA | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/17/2018 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Cardiology | ||||||
| 02/13/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2017 | Neos Therapeutics, LP | Adzenys XR-ODT (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: ADHD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 556 | 815 | $105,932 | $36,038 |
| 2022 | 12 | 2,734 | 4,832 | $659,688 | $227,688 |
| 2021 | 20 | 3,017 | 5,313 | $591,262 | $231,345 |
| 2020 | 20 | 1,606 | 3,068 | $366,904 | $140,367 |
Total Patients
7,913
Total Services
14,028
Medicare Billing
$635,437
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | Office | 2023 | 83 | 90 | $25,634 | $12,175 | 47.5% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2023 | 157 | 168 | $33,600 | $12,128 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 30 | $9,552 | $2,516 | 26.3% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2023 | 17 | 17 | $4,862 | $2,236 | 46.0% |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | Office | 2023 | 86 | 90 | $18,000 | $2,205 | 12.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 16 | $3,610 | $979.98 | 27.1% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 19 | 19 | $2,005 | $955.32 | 47.6% |
| 87481 | Detection test for candida species (yeast), amplified probe technique | Office | 2023 | 26 | 27 | $2,376 | $928.53 | 39.1% |
| 87500 | Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | Office | 2023 | 20 | 21 | $1,848 | $687.80 | 37.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 30 | 60 | $2,246 | $579.25 | 25.8% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 21 | 22 | $744.55 | $326.18 | 43.8% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 12 | 12 | $795.00 | $271.81 | 34.2% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 26 | 108 | $524.00 | $38.78 | 7.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 14 | 135 | $135.00 | $10.30 | 7.6% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2022 | 319 | 2,054 | $179,960 | $69,937 | 38.9% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2022 | 673 | 805 | $161,000 | $59,185 | 36.8% |
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | Office | 2022 | 311 | 345 | $98,670 | $47,304 | 47.9% |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | Office | 2022 | 579 | 683 | $136,600 | $16,880 | 12.4% |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | Office | 2022 | 241 | 271 | $23,848 | $9,222 | 38.7% |
| 87581 | Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | Office | 2022 | 235 | 260 | $22,880 | $8,787 | 38.4% |
| 87801 | Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | Office | 2022 | 57 | 61 | $6,057 | $4,197 | 69.3% |
| 87481 | Detection test for candida species (yeast), amplified probe technique | Office | 2022 | 88 | 100 | $8,630 | $3,439 | 39.8% |
| 87500 | Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | Office | 2022 | 85 | 93 | $8,184 | $3,226 | 39.4% |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | Office | 2022 | 72 | 79 | $6,952 | $2,721 | 39.1% |
| 87653 | Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | Office | 2022 | 61 | 67 | $5,709 | $2,305 | 40.4% |
About Dr. Jason Junkins, M.D
Dr. Jason Junkins, M.D is a Internal Medicine healthcare provider based in Rainbow City, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114928512.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Junkins, M.D has received a total of $132.70 in payments from pharmaceutical and medical device companies, with $25.97 received in 2022. These payments were reported across 7 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($132.70).
As a Medicare-enrolled provider, Junkins has provided services to 7,913 Medicare beneficiaries, totaling 14,028 services with total Medicare billing of $635,437. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Rainbow City, AL
- Active Since 08/09/2005
- Last Updated 03/12/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1114928512
Products in Payments
- JANUVIA (Drug) $28.72
- General - Pain Management (Device) $25.97
- Repatha (Biological) $23.01
- Adzenys XR-ODT (Drug) $19.80
- KEYTRUDA (Biological) $18.13
- Xofluza (Drug) $17.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.